The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients

Elizabeth Krachey, Kert Viele, Philip C. Spinella, Marie E Steiner, Nicole D Zantek, Roger J. Lewis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Storage of platelets at 4°C compared with 22°C may increase both hemostatic activity and storage duration; however, the maximum duration of cold storage is unknown. We report the design of an innovative, prospective, randomized, Bayesian adaptive, "duration finding" clinical trial to evaluate the efficacy and maximum duration of storage of platelets at 4°C. METHODS: Patients undergoing cardiac surgery and requiring platelet transfusions will be enrolled. Patients will be randomized to receive platelets stored at 22°C up to 5 days or platelets stored at 4°C up to 5 days, 10 days, or 15 days. Longer durations of cold storage will only be used if shorter durations at 4°C appear noninferior to standard storage, based on a four-level clinical hemostatic efficacy score with a NIM of a half level. A Bayesian linear model is used to estimate the hemostatic efficacy of platelet transfusions based on the actual duration of storage at 4°C. RESULTS: The type I error rate, if platelets stored at 4°C are inferior, is 0.0247 with an 82% probability of early stopping for futility. With a maximum sample size of 1,500, the adaptive trial design has a power of over 90% to detect noninferiority and a high probability of correctly identifying the maximum duration of storage at 4°C that is noninferior to 22°C. CONCLUSION: An adaptive, duration-finding trial design will generate Level I evidence and allow the determination of the maximum duration platelet storage at 4°C that is noninferior to standard storage at 22°C, with respect to hemostatic efficacy. The adaptive trial design helps to ensure that longer cold storage durations are only explored once substantial supportive data are available for the shorter duration(s) and that the trial stops early if continuation is likely to be futile.

Original languageEnglish (US)
Pages (from-to)S41-S46
JournalThe journal of trauma and acute care surgery
Volume84
Issue number6S Suppl 1
DOIs
StatePublished - Jun 1 2018

Fingerprint

Blood Platelets
Clinical Trials
Hemostatics
Temperature
Platelet Transfusion
Medical Futility
Sample Size
Thoracic Surgery
Linear Models

Cite this

The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. / Krachey, Elizabeth; Viele, Kert; Spinella, Philip C.; Steiner, Marie E; Zantek, Nicole D; Lewis, Roger J.

In: The journal of trauma and acute care surgery, Vol. 84, No. 6S Suppl 1, 01.06.2018, p. S41-S46.

Research output: Contribution to journalArticle

@article{5a1b494b7db64bc9b136618f26461211,
title = "The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients",
abstract = "BACKGROUND: Storage of platelets at 4°C compared with 22°C may increase both hemostatic activity and storage duration; however, the maximum duration of cold storage is unknown. We report the design of an innovative, prospective, randomized, Bayesian adaptive, {"}duration finding{"} clinical trial to evaluate the efficacy and maximum duration of storage of platelets at 4°C. METHODS: Patients undergoing cardiac surgery and requiring platelet transfusions will be enrolled. Patients will be randomized to receive platelets stored at 22°C up to 5 days or platelets stored at 4°C up to 5 days, 10 days, or 15 days. Longer durations of cold storage will only be used if shorter durations at 4°C appear noninferior to standard storage, based on a four-level clinical hemostatic efficacy score with a NIM of a half level. A Bayesian linear model is used to estimate the hemostatic efficacy of platelet transfusions based on the actual duration of storage at 4°C. RESULTS: The type I error rate, if platelets stored at 4°C are inferior, is 0.0247 with an 82{\%} probability of early stopping for futility. With a maximum sample size of 1,500, the adaptive trial design has a power of over 90{\%} to detect noninferiority and a high probability of correctly identifying the maximum duration of storage at 4°C that is noninferior to 22°C. CONCLUSION: An adaptive, duration-finding trial design will generate Level I evidence and allow the determination of the maximum duration platelet storage at 4°C that is noninferior to standard storage at 22°C, with respect to hemostatic efficacy. The adaptive trial design helps to ensure that longer cold storage durations are only explored once substantial supportive data are available for the shorter duration(s) and that the trial stops early if continuation is likely to be futile.",
author = "Elizabeth Krachey and Kert Viele and Spinella, {Philip C.} and Steiner, {Marie E} and Zantek, {Nicole D} and Lewis, {Roger J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/TA.0000000000001876",
language = "English (US)",
volume = "84",
pages = "S41--S46",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "6S Suppl 1",

}

TY - JOUR

T1 - The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients

AU - Krachey, Elizabeth

AU - Viele, Kert

AU - Spinella, Philip C.

AU - Steiner, Marie E

AU - Zantek, Nicole D

AU - Lewis, Roger J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - BACKGROUND: Storage of platelets at 4°C compared with 22°C may increase both hemostatic activity and storage duration; however, the maximum duration of cold storage is unknown. We report the design of an innovative, prospective, randomized, Bayesian adaptive, "duration finding" clinical trial to evaluate the efficacy and maximum duration of storage of platelets at 4°C. METHODS: Patients undergoing cardiac surgery and requiring platelet transfusions will be enrolled. Patients will be randomized to receive platelets stored at 22°C up to 5 days or platelets stored at 4°C up to 5 days, 10 days, or 15 days. Longer durations of cold storage will only be used if shorter durations at 4°C appear noninferior to standard storage, based on a four-level clinical hemostatic efficacy score with a NIM of a half level. A Bayesian linear model is used to estimate the hemostatic efficacy of platelet transfusions based on the actual duration of storage at 4°C. RESULTS: The type I error rate, if platelets stored at 4°C are inferior, is 0.0247 with an 82% probability of early stopping for futility. With a maximum sample size of 1,500, the adaptive trial design has a power of over 90% to detect noninferiority and a high probability of correctly identifying the maximum duration of storage at 4°C that is noninferior to 22°C. CONCLUSION: An adaptive, duration-finding trial design will generate Level I evidence and allow the determination of the maximum duration platelet storage at 4°C that is noninferior to standard storage at 22°C, with respect to hemostatic efficacy. The adaptive trial design helps to ensure that longer cold storage durations are only explored once substantial supportive data are available for the shorter duration(s) and that the trial stops early if continuation is likely to be futile.

AB - BACKGROUND: Storage of platelets at 4°C compared with 22°C may increase both hemostatic activity and storage duration; however, the maximum duration of cold storage is unknown. We report the design of an innovative, prospective, randomized, Bayesian adaptive, "duration finding" clinical trial to evaluate the efficacy and maximum duration of storage of platelets at 4°C. METHODS: Patients undergoing cardiac surgery and requiring platelet transfusions will be enrolled. Patients will be randomized to receive platelets stored at 22°C up to 5 days or platelets stored at 4°C up to 5 days, 10 days, or 15 days. Longer durations of cold storage will only be used if shorter durations at 4°C appear noninferior to standard storage, based on a four-level clinical hemostatic efficacy score with a NIM of a half level. A Bayesian linear model is used to estimate the hemostatic efficacy of platelet transfusions based on the actual duration of storage at 4°C. RESULTS: The type I error rate, if platelets stored at 4°C are inferior, is 0.0247 with an 82% probability of early stopping for futility. With a maximum sample size of 1,500, the adaptive trial design has a power of over 90% to detect noninferiority and a high probability of correctly identifying the maximum duration of storage at 4°C that is noninferior to 22°C. CONCLUSION: An adaptive, duration-finding trial design will generate Level I evidence and allow the determination of the maximum duration platelet storage at 4°C that is noninferior to standard storage at 22°C, with respect to hemostatic efficacy. The adaptive trial design helps to ensure that longer cold storage durations are only explored once substantial supportive data are available for the shorter duration(s) and that the trial stops early if continuation is likely to be futile.

UR - http://www.scopus.com/inward/record.url?scp=85063707418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063707418&partnerID=8YFLogxK

U2 - 10.1097/TA.0000000000001876

DO - 10.1097/TA.0000000000001876

M3 - Article

VL - 84

SP - S41-S46

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 6S Suppl 1

ER -